ACADIAN ASSET MANAGEMENT LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 39 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2018. The put-call ratio across all filers is 0.60 and the average weighting 0.0%.

Quarter-by-quarter ownership
ACADIAN ASSET MANAGEMENT LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2021$118,000
-77.7%
35,893
-74.2%
0.00%
-100.0%
Q2 2021$529,000
+1025.5%
139,333
+1035.7%
0.00%
Q3 2018$47,00012,2680.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2018
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders